Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-au-troisieme-trimestre-croissance-du-chiffre-daffaires-et-du-resultat-dans-toutes-les-divisionsChiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses…
- https://www.novartis.com/news/media-releases/novartis-phase-iii-study-demonstrates-adjuvant-tafinlar-mekinist-reduced-risk-disease-recurrence-53-patients-resected-braf-v600-mutation-positive-melanomaThe three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
- https://www.novartis.com/news/media-releases/novartis-presents-new-analysis-demonstrating-amg-334-erenumab-significantly-reduced-monthly-migraine-days-patients-who-failed-previous-preventive-therapiesAMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need Dedicated…
- https://www.novartis.com/news/media-releases/novartis-landmark-phase-iii-trial-shows-fingolimod-significantly-reduces-relapses-children-and-adolescents-msPhase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet…
- https://www.novartis.com/news/media-releases/novartis-announces-ceo-joseph-jimenez-retire-from-novartis-2018-vasant-narasimhan-appointed-ceo-effective-february-1-2018Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The…
- https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twiceFirst-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer…
- https://www.novartis.com/news/media-releases/novartis-announces-analysis-published-lancet-showing-acz885-reduced-lung-cancer-mortality-77-cantos-study-further-studies-plannedReview of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is…
- https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885-reduces-cardiovascular-riskStudy showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in…
- https://www.novartis.com/news/media-releases/novartis-appoints-bertrand-bodson-chief-digital-officerNew leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury'…
- https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-eu-approval-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitorApproval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole…
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 263
- › Next page